Observational Study to Understand Patients' and Physicians' Attitudes to Statins in TurkeY

AstraZeneca500 enrolled

Overview

In Turkey statin compliance is lower than EU countries. (EURIKA). We will assess the underlying causes of statin incompliance. The investigators will build patient and physician education programs to improve compliance in TURKEY. Our aim is to assess patients' and physicians' attitudes to statins by mean of HABIT Patient and Physician survey respectively.

Observational study to understand patients' and physicians' attitudes to Statins in TurkeY

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Hypercholesterolemia

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Provision of subject informed consent Female and/or male aged over 18 years, * Diagnosis of hypercholesterolemia according to ICD-10 classification * Receiving at least one prescription of one statin during the last 12 months and to be an outpatient. Exclusion Criteria: * Receiving statin at the time of admittance * Patients unable to read and/or understand the study questionnaires * Pregnant women, * Patients participating in randomized clinical trials and patients included in this study once

Locations (10)

Research Site

Ankara, Turkey (Türkiye)

Research name

Aydin, Turkey (Türkiye)

Research Site

Diyarbakır, Turkey (Türkiye)

Research Site

Hatay, Turkey (Türkiye)

Outcomes

Primary Outcomes

HABIT scores for the patients of the following questionnaire items (see description)

* Total score * Effectiveness of cholesterol-lowering medications * Association of high doses with adverse experiences * Risk of high cholesterol * Severity of high cholesterol * Frustration with the process of care * Difficulty in following advice / making changes * Doctor-patient communication * Communication about cholesterol

Time frame: Participants will be questioned at visit one, visits will take part during 25 weeks of expected study period

HABIT scores for the physicians of the following questionnaire items (see description)

* Total score * Effectiveness of statins * Patients view titration negatively * Risk associated with higher doses * Close enough to goal * Urgency of getting to goal * Utility of diet and exercise * Time and resources to counsel patients * Physician self-efficacy in treating patients to goal

Time frame: Participants will be questioned at visit one, visits will take part during 25 weeks of expected study period

Secondary Outcomes

Socio-demographics terms

* Age * Sex * Smoking habits * Educational level * Professional status * Place of residence * Income level * Healthcare insurance level

Time frame: Participants will be questioned at visit one, visits will take part during 25 weeks of expected study period

Clinical characteristics

* Date of diagnosis * Current disease status: Physical examination results (vital signs and anthropometric measurements) * Cardiovascular risk factors * Relevant co-morbidities * Cholesterol levels (LDL-C) at inclusion (if available) * Number of hospitalizations during the last 12 months * Duration of statin use in the past year

Time frame: Participants will be questioned at visit one, visits will take part during 25 weeks of expected study period

Clinical characteristics (continuation)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.